Recent attempts at rebuilding the myocardium using stem cells have yielded disappointing results. The lack of a supporting vasculature may, in part, explain these disappointing findings. However, concerns over possible side effects have hampered attempts at revascularizing the infarcted myocardium using systemic delivery of proangiogenic compounds. 
Recently, there has been much excitement and interest in developing regenerative strategies for curing heart disease using cell-based therapies. However, stemcell therapies have only resulted in modest improvements, if any, in cardiac function (1) (2) (3) , and in some cases, these modest improvements may be a result of angiogenic cytokines released from transplanted stem cells, and not the division, differentiation, and incorporation of new stem cells into the existing myocardium (4 -6) . The lack of a supporting microenvironment, and especially a microvascular framework, that is essential for stem-cell survival, engraftment, and proliferation, may be the key to unlocking the full potential of stem-cell therapies (7) .
Myocardial infarction (MI) involves loss of blood flow in a specific region of the heart and the extent of the damage is dependant on location of the blockage and time after MI. Deep within the infarct area, cells devoid of an oxygen supply become apoptotic and/or terminally necrotic within hours and cannot be rescued even with reperfusion. However, there is a transitional "border zone" region, which lies between the normal, well-vascularized myocardium and the necrotic, irreversibly ischemic myocardium, where the reduced blood flow is accompanied by the up-regulation of the inflammatory response. Recent studies have shown that this up-regulation of the inflammatory response leads to increased expression of several cell-adhesion molecules (e.g., P-selectin and ICAM-1) in the vasculature of this region (8) . This increased expression not only leads to the recruitment of leukocytes and other circulating cells (e.g., stem cells) to the infarct region (9) but also can be used to selectively target drugs to the altered endothelial surface (7) .
Transfection of genes encoding for angiogenic proteins or direct administration of recombinant proteins have been used to initiate angiogenesis in diseased tissue (7, 10) . In animal models of coronary artery disease (CAD), large systemic doses of vascular endothelial growth factor (VEGF) resulted in a modest improvement in myocardial perfusion, but any observed functional improvements were less consistent (11) . Clinically, it is difficult to quantitatively assess vascular improvement in patients treated with therapeutic angiogenesis, although they experienced a modest reduction in angina and an increase in exercise time (12) .
Our own data indicate that systemic intravenous delivery of VEGF results in some improvements in vascular density but not cardiac function (13) . However, administration of large systemic doses of compounds such as VEGF can have serious side effects, such as the development of neoplasms, diabetic retinopathy, rheumatoid arthritis, and atherosclerosis (14 -19) . Targeted delivery of an adequate therapeutic dose of proangiogenic compounds, such as VEGF, to the border zone of the infarcted myocardium could initiate the local growth of new vessels, while minimizing potential side effects in distant tissue. Previously, we have shown that the up-regulation of the cell-adhesion molecule P-selectin on the luminal surface of microvasculature in the border zone of the infarct can be used to selectively deliver clinically relevant nanoparticles to the infarcted tissue (8) . P-selectin is a glycosylated protein that is stored in granules in endothelial cells and platelets and is expressed on the surface of the endothelium in response to inflammatory stimuli (20) . P-selectin is one of the major molecules responsible for leukocyte rolling in inflammation and has been shown to be expressed in a number of different diseases, including ischemia-reperfusion injury (21) . P-selectin expression in the infarcted heart was shown to be significantly increased compared to normal heart tissue in postmortem humans (22) and animals (8, 23, 24) .
In this study, we have developed a methodology for generating anti-P-selectin-conjugated liposomes containing VEGF and have used these immunoliposomes to test the hypothesis that selective targeting of these immunoliposomes to the infarcted tissue results in significant improvements in cardiac function and vascular structure after MI.
MATERIALS AND METHODS

Rat MI model
An MI model in 6-wk-old male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN, USA), weighing ϳ200 g, was used in these experiments (25) . In anesthetized rats (2% isoflurane gas), a left thoracotomy and pericardiotomy was performed, and a 6-0 silk suture (Ethicon, Somerville, NJ, USA) was placed around the left anterior descending coronary artery (LADA) to create a (LV) anterior transmural MI. The vessel was ligated, the chest was closed, and lungs were reinflated using positive end-expiratory pressure. The MI was detected by evidence of elevated ST segment and the appearance of Q waves on ECG and echocardiography. 
Preparation of stealth liposomes
Liposomes were composed of 50 mol% hydrogenated soy l-␣-phosphatidylcholine, 45 mol% cholesterol, 3 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[(polyethylene glycol)2000] (DSPE-PEG2000), and 2 mol% DSPE-PEG-maleimide (Avanti, Alabaster, AL, USA). After mixing, the lipids were dried under vacuum overnight, and then the lipid film was rehydrated in 40°C deionized water to form vesicles. The lipids were extruded (Lipex, Vancouver, BC, Canada) 10 times with a 0.2-m filter (Nucleopore; General Electric Co., Pleasanton, CA, USA), yielding a liposome diameter of 180 Ϯ 13 nm. The liposome diameter was measured by optical scattering using a particle sizer (Zetasizer 1000 HAS; Malvern Instruments, Malvern, UK). The particles were 0.180 Ϯ 0.035 m, close to the size of the Nucleopore filter (0.2 m), suggesting that a singleliposome suspension was formed.
Preparation of immunoliposomes conjugated to anti-P-selectin
Immunoliposomes were conjugated to IgG2a mAb RMP-1 to rat P-selectin (26) . The anti-P-selectin storage buffer was removed using a Microcon YM-30 centrifuge filter (Millipore, Billerica, MA, USA). The immunoliposomes were then suspended in a 60-M triethanolamine (TEA), 100 mM NaCl, and 1 mM EDTA buffer (pH 8.0). The antibody was then thiolated by incubating with iminothiolane for 1 h, then resuspended in Tris-saline buffer (pH 6.0) using a Microcon YM-30 filter. The thiolated antibody was then incubated with the liposomes overnight at 4°C to attach to the maleimide group on the DSPE-PEG2000 component of the liposomes. The unconjugated antibody was separated from the liposomes by ultracentrifugation for 1 h at 30,000 rpm.
Incorporation of VEGF into the immunoliposomes
After the initial formation of the antibody-conjugated immunoliposomes, human VEGF 165A (Genentech, San Francisco, CA, USA) was encapsulated into immunoliposomes following published techniques (27) . The immunoliposomes were freeze-dried under vacuum overnight. The immunoliposomes were rehydrated in 1 ml of a Tris buffer (pH 7.4) solution containing 100 g of VEGF at 40°C, vortexed until vesicles were fully reformed, and incubated at room temperature for 1 h. Free VEGF (not encapsulated) was separated from the immunoliposomes with a Hi Trap heparin HP Column (GE Healthcare, Piscataway, NJ, USA). Immunoliposomes were then resuspended to a working 10 mM lipid concentration. The size of the liposomes was measured over a period of several weeks. It was found that the liposomes remained stable up to 2 wk after production (28) . Liposomes made for this study were used within 3 d of production.
Treatment protocol in MI rats
We have previously shown that P-selectin has peak up-regulation times of 1 and 4-h post-MI and that immunoliposomes can be successfully targeted to the MI tissue by either injecting them immediately after MI or 4 h after MI (8) . Therefore, to reduce stress on the animals, each animal received a dose of 0.1 ml of 10 mM (lipid concentration) anti-P-selectin immunoliposomes via tail vein immediately after induction of MI, resulting in an overall VEGF dose of 0.12 g/kg animal weight.
Control animals received either systemic VEGF treatment, empty (no VEGF) anti-P-selectin-conjugated immunoliposomes, VEGF immunoliposomes conjugated with IgG (nontargeted), or no treatment. Systemic VEGF treatments were administered via tail-vein injections over 3 d post-MI, during which the animals received a total of 30 g/kg of VEGF, and functional parameters were measured on d 9, 16, and 28 post-MI (25) .
Echocardiographic protocol
Serial echocardiographic assessment was performed for the purpose of evaluating regional wall function, using standard functional measurements (29) . The echocardiograms were performed after sedation with intramuscular (i.m.) injection of xylazine (10 mg/kg) and ketamine (50 mg/kg). After anesthesia, each animal was shaved on the chest and placed in the supine position for imaging. If the quality of images was fair, the animal was repositioned in the left lateral decubitus position to allow better probe contact with the heart. Imaging began after a period of 5 min after the administration of sedation, to allow animals to stabilize. A Philips Sonos 5500 machine (software package Version D.1; Philips, Amsterdam, The Netherlands) was used to obtain 2-dimensional images. A multifrequency transducer set at 12 MHz was used for 2-dimensional imaging. Imaging was performed using a depth of 2 cm. Parasternal short-axis images were taken at the midpapillary muscle level for 6 cardiac cycles before images were recorded. These echo measurements were highly reproducible when analyzed by different operators (data not shown).
Regional wall motion assessment was used to give a noninvasive evaluation of LV function chamber dimensions. The variables obtained included LV end diastolic dimension (LVEDD; mm) and LV end systolic dimension (LVESD; mm). In addition, LV wall displacement (LVWD) was defined as the peak-to-peak amplitude of the infarcted LV wall motion. Fractional shortening (FS) was used to estimate LV regional function:
Quantification of the number of anatomical and perfused vessels
The same rats that underwent echocardiography were sacrificed 4 wk after MI, and changes in vascular perfusion and density were determined. As described previously (25) , a series of novel staining techniques used to characterize tumor vascularity and perfusion (30) was adapted to quantify the changes in the vascular network following an MI. DiOC 7 (3,3Ј-diheptyloxacarbocyanine iodide) (Invitrogen, Carlsbad, CA, USA) was injected into the tail vein, and after 1 min, animals were sacrificed, and hearts were removed, frozen, and sectioned. DiOC 7 has been shown to stain only perfused vessels in both cardiac tissue and tumors (30, 31) . Staining for CD31 (BD Biosciences, Franklin Lakes, NJ, USA) was used to identify anatomical vessels, and DiOC 7 staining was used to identify perfused vessels. A modification of our existing methods was used to quantify the number of vessels in treated and untreated animals (25) . These immunohistological staining techniques can be used to measure the distance between cells and their nearest anatomical or perfused vessel. The distribution of distances from the nearest perfused vessel can be used as an index of effective oxygen diffusion distance in tissue (25, 31, 32) .
Statistical analysis
Data are presented as means Ϯ se unless otherwise noted. Analysis of variance (SigmaStat 3.1; Systat Software, San Jose, CA, USA) was used to determine significant differences in cardiac function among between the experimental groups: VEGF anti-P-selectin-conjugated immunoliposome treatment, systemic VEGF treatment, empty (no VEGF) anti-P-selectinconjugated immunoliposome treatment, VEGF IgG-conjugated immunoliposome (nontargeted) treatment, or no treatment. The Kolmogorov-Smirnov Test (Statgraphics Centurion XV; StatPoint Inc., Herndon, VA, USA) was used to determine significant differences in the distribution of distances to the nearest perfused vessel data. Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
Changes in cardiac function after MI as determined by echocardiography
Changes in cardiac function in untreated and targeted VEGF therapy-treated MI animals were measured using echocardiography. Figure 1 shows an M-mode trace of LV heart function of a normal heart (Fig. 1A) , an untreated infarcted heart (Fig. 1B) , and an infarcted heart treated with targeted VEGF therapy (Fig. 1C) . The loss of LV free wall motion (upper wall in Fig. 1B) , as well as the increase in LVEDD (distance during diastole between upper and lower wall in B, Fig. 1B ), 4 wk after MI is moderated as a result of targeted VEGF therapy (Fig. 1C) as compared with the untreated MI group. Echocardiograms taken 1 to 3 d after surgery may provide some insight into cardiac function immediately following the induction of an MI. Although targeted VEGF therapy appears to result in a significant improvement in FS as early as 1 d after MI, these results must be interpreted cautiously; the quality of echocardiographic images during the first few days after an MI tend to be poor due to the inflammation of tissue following surgery. However, at the end time point of 4 wk after MI, animals treated with anti-P-selectin-conjugated VEGF immunoliposomes clearly showed significant improvements in cardiac function compared to controls (see Fig. 2 ). Administration of blank immunoliposomes (i.e., no VEGF), a much higher dose of systemic VEGF, or IgG-conjugated VEGF immunoliposomes did not result in significant improvements in cardiac function.
The most notable change in cardiac function immediately after an MI is diminished LV wall motion due to myocyte necrosis. Targeted VEGF therapy moderated this Figure 1 . Targeted VEGF therapy resulted in significant improvements in LV wall motion 4 wk after MI. M-mode trace of LV heart function of a normal heart (A), an untreated infarcted heart (B), and an infarcted heart treated with targeted VEGF therapy (C).
loss of LV wall motion as compared to untreated rats starting at 1 wk after MI and persisting up to 4 wk after MI (Fig. 3) .
As the heart remodels in the weeks following an MI, the compensatory processes that occur in response to increased wall stress ultimately lead to significant LV dilatation and dysfunction. Targeted VEGF therapy resulted in an improvement (reduction) in LVEDD starting at 2 wk and persisting up to 4 wk after MI compared to untreated MI rats and MI rats treated with blank immunoliposomes, systemic VEGF, or IgG-conjugated VEGF immunoliposomes (Fig. 4) .
Changes in vascular density and perfusion after MI as determined by histochemical staining analysis
Changes in cardiac function were accompanied by improvements in vasculature as indicated by DiOC 7 staining of perfused vessels and CD31 staining of anatomical vessels, as shown in Fig. 5 . Targeted VEGF therapy resulted in a significant increase in the number of anatomical vessels and perfused vessels (21 and 74%, respectively) in 4-wk-post-MI border zone myocardium compared to the untreated rats (Fig. 6) . In addition, the fraction of anatomical vessels in the border zone that were perfused was significantly (PϽ0.01) increased after targeted VEGF therapy; i.e., 70% of vessels in the targeted VEGF therapy group were perfused, while only 49% of vessels in the untreated group were perfused. Targeted VEGF therapy restored the fraction of perfused vessels to that observed in normal cardiac tissue (25) . As shown in Fig. 7 , targeted VEGF therapy resulted in significant improvements (decrease) in the distance to the nearest perfused vessel as compared to untreated MI animals. The average distance to the nearest perfused vessel (meanϮse) in normal, untreated, and targeted-VEGF-treated animals was 4.5 Ϯ 2.4, 33.2 Ϯ 4.9, and 18.9 Ϯ 3.7 m, respectively.
No VEGF-treated animals died or suffered from observable symptoms during the course of this study. An independent pathological examination of tissue indicated that targeted VEGF therapy resulted in no pathological changes in any of the major organs. 
DISCUSSION
In this study, we have shown that treating infarcted myocardial tissue with a single dose of anti-P-selectinconjugated immunoliposomes containing VEGF results in significant improvements in cardiac function 4 wk after MI. These improvements in cardiac function were accompanied by a 21% increase in the number of anatomical vessels and a 74% increase in the number of perfused vessels in the MI region of treated animals, compared to untreated animals. In addition, the fraction of perfused vessels in targeted VEGF-treated animals was increased significantly to reach the levels needed to sufficiently oxygenate cardiac tissue (25) . Although improvements in vascular density appear to be modest compared to improvements in cardiac function, VEGF has been shown to have vascular-independent effects on cardiac function (5) . In other words, small improvements in vascular function could potentially result in much larger improvements in cardiac function.
While current therapies, in most part, aim to manage heart disease, the emergence of a number of cell-based therapies represents a paradigm shift toward curing heart disease. However, the lack of a supporting vasculature for the highly oxygen dependent cardiomyocytes may, in part, explain why recent attempts at rebuilding the myocardium using stem cells have yielded disappointing results (2, 3) . Furthermore, recent evidence indicates that even the limited improvements in cardiac function after stem-cell treatment may be, in part, due to angiogenesis (5) . Creation of a suitable microenvironment, including a functioning microvasculature, before the application of stem-cell therapies may be an important strategy for not only ensuring the successful engraftment of transplanted stem cells (7), but also preventing or significantly moderating scarring and cardiac remodeling during the later stages. Development of novel approaches to selectively target proangiogenic compounds to MI tissue may not only minimize the side effects of these compounds but also play a key role in improving the outcome of many regenerative (e.g., cell-based) therapies. Currently, we are studying the optimal regime by which this proangiogenic therapy can be combined with stemcell therapy to successfully regenerate diseased cardiac tissue in a clinical setting.
In this study, the observed improvements in cardiac function persisted up to 4 wk after MI and correlated with the observed improvements in vascular density and perfusion. Nevertheless, the observed early improvement in cardiac function in our study may be due to the early exposure of the cardiac tissue to VEGF, which could delay the onset of myocardial apoptosis and cardiac remodeling (10, (33) (34) (35) (36) (37) (38) . This would further highlight the importance of early intervention in attempts to limit cardiac remodeling and/or rebuilding cardiac tissue after an MI. While injection of VEGF immediately following the induction of MI may not represent the most clinically relevant model, our preliminary data (not shown) and previous studies (8) have shown that administration of targeted therapies between induction of the MI and up to 4 h post-MI result in similar improvements in cardiac function and vascular structure.
Previous studies have shown that the administration of large systemic doses (total dose of 1-30 g/kg animal weight) of VEGF over several days after MI results in modest improvements in vascular density in the MI region, but these improvements do not necessarily lead to significant improvements in cardiac function (39, 40) . The large doses of VEGF required in these systemic administrations may be due to its very short half-life (several minutes) in plasma (41) . This half-life may be extended in immunoliposome formulations, where encapsulated VEGF is protected from immediate degradation during circulation in the blood. In our studies, a single dose of 0.12 g/kg (Ͻ1% of typical systemic doses) targeted VEGF using anti-Pselectin-conjugated immunoliposomes resulted in significant improvements in cardiac function and vascular structure up to 4 wk after MI. However, it must be noted that many systemic VEGF therapies have been initiated several days after MI, thereby missing the possible beneficial effects of early VEGF exposure.
Given that a single dose of targeted VEGF therapy resulted in significant improvement in cardiac function, multiple dosing and optimization of the time point at which these doses are administered could potentially result in even larger improvements in cardiac function and vascular structure. For example, the fact that several different adhesion molecules are maximally up-regulated at different times after MI can be used to selectively deliver multiple and sustained doses of VEGF and/or other angiogenic factors over time. Further studies are needed to clarify what doses of, and at what time scale, angiogenic compounds need to be administered to maximize the effectiveness of these treatments, as well as optimizing treatments combining stem cells and targeted proangiogenic therapy to treat MIs in a clinical setting.
Targeted drug delivery to diseased cardiac tissue provides a safer and more effective means of providing a vascular framework after an MI, which in and of itself results in improved cardiac function. Furthermore, this strategy can also be combined with other treatments, e.g., stem-cell therapies, whose limited effectiveness may be due, in part, to the loss of blood flow after the onset of an MI.
